Mylan and epinephrene in the US comes to mind as the most egregious[1]. The reason we don't see as many clear examples is because, as you noted, reputational ef

Mylan and epinephrene in the US comes to mind as the most egregious[1]. The reason we don't see as many clear examples is because, as you noted, reputational effects will usually influence market leaders to try to generate more profit without catching the ire of powerful anti-competitive bodies. In Canada, our band of oligopolies is well known (telecoms and banks primarily)[2], and past and future attempts[3] are difficult to implment due to our low population density[4]. [1] https://www.goodrx.com/blog/epipen-price-change-since-mylan-released-generic-epinephrine/ https://www.goodrx.com/blog/epipen-price-change-since-mylan-... [2] https://this.org/2018/11/30/canada-has-an-oligopoly-problem-and-we-need-to-fix-it/ https://this.org/2018/11/30/canada-has-an-oligopoly-problem-... [3] https://financialpost.com/opinion/the-crtcs-proposals-for-wireless-competition-will-hurt-the-sector-not-help-it https://financialpost.com/opinion/the-crtcs-proposals-for-wi... [4] https://www.statista.com/statistics/271206/population-density-in-canada/ https://www.statista.com/statistics/271206/population-densit...